Citigroup Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $795.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by Citigroup from $895.00 to $795.00 in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity Group started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Morgan Stanley dropped their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $693.23 on Tuesday. Regeneron Pharmaceuticals has a 1-year low of $666.25 and a 1-year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $76.18 billion, a PE ratio of 17.15, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. The firm’s 50 day simple moving average is $744.16 and its 200 day simple moving average is $954.41.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp raised its holdings in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock worth $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after purchasing an additional 11,499 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Regeneron Pharmaceuticals by 12.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock worth $567,864,000 after purchasing an additional 59,769 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Regeneron Pharmaceuticals by 0.7% during the second quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock valued at $357,945,000 after buying an additional 2,270 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.